As of 2025-06-21, the Relative Valuation of Fulcrum Therapeutics Inc (FULC) is (3.34) USD. This relative valuation is based on P/E multiples. With the latest stock price at 6.36 USD, the upside of Fulcrum Therapeutics Inc based on Relative Valuation is -152.5%.
The range of the Relative Valuation is (3.33) - (3.20) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.0x - 17.8x | 17.4x |
| Forward P/E multiples | 18.5x - 21.5x | 19.6x |
| Fair Price | (3.33) - (3.20) | (3.34) |
| Upside | -152.4% - -150.3% | -152.5% |
| Date | P/E |
| 2025-06-18 | -35.30 |
| 2025-06-17 | -35.69 |
| 2025-06-16 | -37.74 |
| 2025-06-13 | -38.02 |
| 2025-06-12 | -37.63 |
| 2025-06-11 | -37.91 |
| 2025-06-10 | -38.30 |
| 2025-06-09 | -39.52 |
| 2025-06-06 | -40.24 |
| 2025-06-05 | -39.47 |
| 2025-06-04 | -39.02 |
| 2025-06-03 | -39.05 |
| 2025-06-02 | -38.63 |
| 2025-05-30 | -38.16 |
| 2025-05-29 | -39.24 |
| 2025-05-28 | -38.30 |
| 2025-05-27 | -35.25 |
| 2025-05-23 | -35.75 |
| 2025-05-22 | -33.97 |
| 2025-05-21 | -34.69 |
| 2025-05-20 | -36.13 |
| 2025-05-19 | -38.47 |
| 2025-05-16 | -38.19 |
| 2025-05-15 | -36.63 |
| 2025-05-14 | -31.25 |
| 2025-05-13 | -32.14 |
| 2025-05-12 | -31.53 |
| 2025-05-09 | -29.81 |
| 2025-05-08 | -30.03 |
| 2025-05-07 | -28.14 |
| 2025-05-06 | -29.70 |
| 2025-05-05 | -31.81 |
| 2025-05-02 | -31.19 |
| 2025-05-01 | -24.31 |
| 2025-04-30 | -21.37 |
| 2025-04-29 | -20.26 |
| 2025-04-28 | -19.82 |
| 2025-04-25 | -19.59 |
| 2025-04-24 | -19.48 |
| 2025-04-23 | -19.93 |
| 2025-04-22 | -20.26 |
| 2025-04-21 | -19.21 |
| 2025-04-17 | -18.26 |
| 2025-04-16 | -16.98 |
| 2025-04-15 | -16.87 |
| 2025-04-14 | -16.21 |
| 2025-04-11 | -14.93 |
| 2025-04-10 | -14.57 |
| 2025-04-09 | -15.99 |
| 2025-04-08 | -14.65 |